Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
Holding RYTM?
Track your performance easily
RYTM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.67 - $55.64
Previous Close$48.55
Volume455.25K
Average Volume (3M)392.30K
Market Cap
$2.97B
Enterprise Value$2.65B
Total Cash (Recent Filing)$319.13M
Total Debt (Recent Filing)$4.12M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Nov 05, 2024EPS Estimate
-$0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.37
Shares Outstanding61,133,765
10 Day Avg. Volume307,726
30 Day Avg. Volume392,298
Standard Deviation0.35
R-Squared0.10
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)75.86
Price to Sales (P/S)29.16
Price to Cash Flow (P/CF)-25.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue26.07
Enterprise Value/Gross Profit38.94
Enterprise Value/Ebitda-13.41
Forecast
1Y Price Target
$61.73Price Target Upside27.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Rhythm Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRhythm reported 2Q'24 EPS of -$0.55 vs. -$0.71 for consensus and our estimate.
Pipeline DevelopmentsItaly has approved an early access program for 6-to-24-year-old HO patients.
Sales GrowthThe BBS launch continues to see strong, steady growth, with over 100 new US scrips and 70 reimbursement approvals.
Bears Say
Medicaid ReimbursementOne state Medicaid program found its Bardet-Biedl syndrome (BBS) payments were higher than expected, so it stopped covering Imcivree.
Patient RetentionApproximately 30 patients came off therapy due to the single state Medicaid issue.
Sales PerformanceSales were lighter than consensus modeled, leading to a less steep uptake for Imcivree.
---
Ownership Overview
0.58% Insiders
25.85% Mutual Funds
0.32% Other Institutional Investors
61.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $21.67 and its highest was $55.64 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Nov 05, 2024 which is tomorrow.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on Aug 06, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.709 by $0.159.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -$0.81.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 61,133,766 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.709. Following the earnings report the stock price went up 0.023%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Among the largest hedge funds holding Rhythm Pharmaceuticals Inc’s share is PRIMECAP Management Co. It holds Rhythm Pharmaceuticals Inc’s shares valued at 300M.
---
Rhythm Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.73 (27.15% Upside)
$61.73 (27.15% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 670.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.68%
12-Months-Change
Fundamentals
Return on Equity
-234.10%
Trailing 12-Months
Asset Growth
23.20%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
---
RYTM Company Deck
---
RYTM Earnings Call
Q2 2024
0:00 / 0:00
---
RYTM Stock 12 Month Forecast
Average Price Target
$61.73
▲(27.15% Upside)
Technical Analysis
Best Analysts Covering RYTM
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+56.47%
reiterated a buy rating 6 months ago
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +56.47% per trade.
---